Background In breast cancer, ER/PgR, HER2, and Ki-67 are important biological markers for
predicting prognosis and making effective treatment decisions. In addition, changes in …

Background Occasionally, breast cancer relapses more than 5 years after initial treatment,
sometimes with highly aggressive disease in such late-recurring patients. This study …

The aim of this study was to evaluate the frequency and prognostic impact of changes in the
estrogen (ER), progesterone (PR) and human epidermal growth factor receptor 2 (HER2) …

Objective To assess the prognostic significance of molecular biomarkers, particularly c-erbB-
2 and p53, through study of prospective clinical data and archival breast cancer tissues for …

The therapeutic strategy for breast cancer is determined by the surrogate subtype, which is
defined by biomarkers, such as estrogen receptor (ER), progesterone receptor (PgR) …

Background: Breast cancer is associated with a relatively good prognosis. Prognostic factors
examined to date are related to early recurrence while those related to late recurrence and …

Background. Obtaining tumor specimens and re‐evaluating targeted markers is
recommended, if possible, in breast cancer patients who relapsed after curative treatment …

The success of current hormonal therapies used in breast cancer patients often depends on
estrogen receptor (ER) status. The simultaneous pathological assessment of primary breast …

Estrogen receptor (ER) and progesterone receptor (PR) are hormone receptors found on
breast cells that pick up hormone signals resulting in cell growth. Similarly, positive human …

Purpose There is cumulative evidence that changes in biomarker status occur frequently
during the metastatic progression of breast cancer and affect treatment response. The …